GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » Intangible Assets

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Intangible Assets : $0.8 Mil (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Paratek Pharmaceuticals's intangible assets for the quarter that ended in Jun. 2023 was $0.8 Mil.


Paratek Pharmaceuticals Intangible Assets Historical Data

The historical data trend for Paratek Pharmaceuticals's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Intangible Assets Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.83 0.83 0.83 0.83 0.83

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.83 0.83 0.83 0.83

Paratek Pharmaceuticals Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Paratek Pharmaceuticals  (NAS:PRTK) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Paratek Pharmaceuticals Intangible Assets Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Executives
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz director C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh director, officer: CEO 75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel officer: CLO, General Counsel & Sec. ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow officer: President & Chief Commercial C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner officer: Chief Development & Regulatory C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie director 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann director LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham director, officer: Exec. Chairman of the Board 890 WINTER STREET, WALTHAM MA 02451
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan officer: Chief Financial Officer 75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Headlines

From GuruFocus